ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 745

An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis

John D. Pauling1,2, Robyn T. Domsic3, Lesley Ann Saketkoo4, Celia Almeida5, Tracy M. Frech6, Francesca Ingegnoli7, Jane Withey8, Hilary Jay8, Emma Dures9, Joanna Robson10, Neil J. McHugh11,12, Ariane L. Herrick13,14, Marco Matucci-Cerinic15, Dinesh Khanna16 and Sarah Hewlett17, 1Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 2Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 3Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Tulane, New Orleans, LA, 5HAS - Nursing and Midwifery, University of the West of England, Bristol, United Kingdom, 6Division of Rheumatology, University of Utah, Salt Lake City, UT, 7Dept. of clinical and community science, Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, 8Patient Research Partner, Bath, United Kingdom, 9Academic Rheumatology, Bristol, University of the West of England, Bristol, Bristol, United Kingdom, 10Rheumatology, University of the West of England (UWE Bristol), Bristol, United Kingdom, 11Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 12Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, 13Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, 14School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 15Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, 16Department of Medicine, University of Michigan Scleroderma Program, Ann Arbor, MI, 17UWE Academic Rheumatology, University of West of England, Bristol, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: patient outcomes, Patient participation, qualitative and systemic sclerosis, Raynaud's phenomenon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Raynaud’s phenomenon (RP) is consistently ranked highest in patient surveys exploring the frequency and impact of disease related manifestations of systemic sclerosis (SSc). SSc-RP is an episodic phenomenon and not easily assessed in the clinical setting. A thorough understanding of the patient experience of SSc-RP is essential if severity and impact are to be captured using patient-reported outcome (PRO) instruments. We report the findings of an international qualitative research study to investigate the patient experience of SSc-RP.

Methods:

Focus groups (FGs) comprising patients with SSc-RP (fulfilling 2013 ACR/EULAR classification criteria) were conducted across 3 scleroderma centers in the United States and United Kingdom, using a topic guide devised by a steering committee comprising qualitative researchers, SSc patients and SSc experts. Participants were enrolled according to an a priori purposive sampling framework ensuring we sought the views of a diverse (geographic, cultural and ethnic) and representative (disease subtype, disease duration, gender and history of digital ulcer disease) cohort of SSc patients. FGs were audio recorded, transcribed, anonymised and analysed using inductive thematic analysis. Additional FGs were conducted until thematic saturation was achieved.

Results:

Forty SSc patients participated in 6 focus groups conducted in Bath (n=2), New Orleans (n=3) and Pittsburgh (n=1). The participant demographics are presented (Table). The patient experience of SSc-RP can be described according to 7 major inter-related themes comprising; physical symptoms, emotional impact, triggers & exacerbating factors, constant vigilance & self-management, impact on daily life, uncertainty and adaptation. A conceptual map demonstrating the inter-relationship of the 7 themes is presented (Figure).

Conclusion:

This is the first qualitative study to explore the patient experience of SSc-RP. The multi-center design and purposive sampling framework ensured experiences were obtained from a diverse and representative SSc cohort. SSc-RP comprises a complex interplay of experiences that result in significant physical/emotional distress, disability and altered social participation which adversely affects health-related quality of life. The themes (and subthemes) identified herein are not captured using existing PRO instruments for assessing SSc-RP. Work to develop a novel PRO instrument for assessing the severity and impact of SSc-RP, comprising domains/items grounded in the patient experience of SSc-RP identified in this work is now underway.

 

Demographics and clinical feature of enrolled patients presented according to purposive sampling framework

Total number of participants:

40

Disease subtype:

 

limited

24

diffuse

16

Sex:

 

Female

34

Male

6

Ethnicity:

 

White/Caucasian

26

Black/African-American

12

Hispanic

2

Disease duration (time since 1st non-Raynaud’s symptom)

 

≥3 years

34

<3 years

6

History of DU disease:

 

Yes

23

No

17


Disclosure: J. D. Pauling, Actelion Pharmaceuticals UK, 2,Actelion Pharmaceuticals UK, 5; R. T. Domsic, None; L. A. Saketkoo, None; C. Almeida, None; T. M. Frech, None; F. Ingegnoli, None; J. Withey, None; H. Jay, None; E. Dures, None; J. Robson, None; N. J. McHugh, None; A. L. Herrick, None; M. Matucci-Cerinic, None; D. Khanna, Actelion, Bayer, BoehringerIngelheim, Chemomab, Corbus, Covis, Cytori,Eicos, EMD Serono, Genentech/Roche, Gilead, GSK, Sanofi-Aventis,UCB Pharma, 5,NIH/NIAMS, NIH/NIAID,Bayer, BMS, Genentech/Roche, Pfizer, 2,Eicos, 4; S. Hewlett, None.

To cite this abstract in AMA style:

Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Frech TM, Ingegnoli F, Withey J, Jay H, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S. An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/an-international-qualitative-research-study-exploring-the-patient-experience-of-raynauds-phenomenon-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-international-qualitative-research-study-exploring-the-patient-experience-of-raynauds-phenomenon-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology